Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company’s IMGN289 Investigational New Drug (IND) application has been accepted by the US FDA and is now active. This enables ImmunoGen to advance IMGN289 into human clinical testing, expected to start in 4Q2013. This is the third IND for a novel, wholly owned anticancer compound to be submitted by ImmunoGen and accepted by the FDA in the past two years.
Help employers find you! Check out all the jobs and post your resume.
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company’s IMGN289 Investigational New Drug (IND) application has been accepted by the US FDA and is now active. This enables ImmunoGen to advance IMGN289 into human clinical testing, expected to start in 4Q2013. This is the third IND for a novel, wholly owned anticancer compound to be submitted by ImmunoGen and accepted by the FDA in the past two years.
Help employers find you! Check out all the jobs and post your resume.
